<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02476253</url>
  </required_header>
  <id_info>
    <org_study_id>9260</org_study_id>
    <nct_id>NCT02476253</nct_id>
  </id_info>
  <brief_title>Sodium Bicarbonate to Treat Severe Acidosis in the Critically Ill</brief_title>
  <acronym>(BICAR-ICU)</acronym>
  <official_title>Sodium Bicarbonate to Treat Severe Acidosis in the Critically Ill : A Multiple Center Randomized Clinical Trial (BICAR-ICU)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the present study is to compare the adjunct treatment of metabolic or mixed
      severe acidosis in the critically ill using Sodium Bicarbonate as a buffer to increase the
      plasma pH vs no buffering therapy.

      The study is a randomized multiple center clinical trial with the outcome as a primary
      endpoint.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Design: randomized multiple center clinical trial, open label

        -  Arms: intravenous 4.2% Sodium Bicarbonate vs no additional treatment

        -  Inclusion: age of 18 yo or above, critically ill patient with a SOFA score of 4 or
           above, lactatemia of 2mmol/l or above, with pH of 7.20 or below and PaCO2 of 45mmHg or
           below and bicarbonatemia of 20mmol/l or below

        -  Exclusion: single respiratory disorder (PaCO2 &gt; 50 mmHg, Bicarbonatemia equal or higher
           than (PaCO2-40)/10 + 24 ; acute diarrhea, ileostomy or biliary drainage ; stage IV
           kidney failure or chronic dialysis ; tubular acidosis, ketoacidosis, high anion gap
           acids poisoning (PEG, aspirin, methanol) ; PaCO2 equal to 45mmHg or above and
           spontaneous breathing, pregnancy, protected patients, moribund patient (life expectancy
           of 48h or below)

        -  Randomization: website randomization with stratification on age, presence of sepsis at
           inclusion, renal failure

        -  Intervention: experimental arm: intravenous 4.2% Sodium Bicarbonate 125 to 250ml in
           30min up to 1000ml/24h. The target is a plasma pH of 7.30 or above.

        -  An interim statistical analysis is planned when 200 patients will be included
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 5, 2015</start_date>
  <completion_date type="Anticipated">October 13, 2017</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite criteria of Day 28 mortality and/or patients with at least one organ failure defined as a SOFA score of 3 or 4</measure>
    <time_frame>Day 0 to Day 28</time_frame>
    <description>Composite criteria of Day 28 mortality and/or patients with at least one organ failure defined as a SOFA score of 3 or 4</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evolution of the organ failure scores</measure>
    <time_frame>Day 0 to Day 28</time_frame>
    <description>use of SOFA score to assess the outcome 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of renal replacement therapy (days)</measure>
    <time_frame>Day 0 to Day 28</time_frame>
    <description>need to renal replacement therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation and ventilatory free days (days)</measure>
    <time_frame>Day 0 to Day 28</time_frame>
    <description>duration of mechanical ventilation and ventilatory free days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of vasopressors administration (h)</measure>
    <time_frame>Day 0 to Day 28</time_frame>
    <description>need for vasopressors and fluids using duration of vasopressor infusion (D0 to D28)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital acquired infections (incidence)</measure>
    <time_frame>Day 0 to Day 28</time_frame>
    <description>hospital acquired infections using United States Centers for Disease Control definitions and a dedicated document</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of intravenous fluid (ml)</measure>
    <time_frame>Day 0 to Day 2</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Metabolic Acidosis</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous 4.2% Sodium Bicarbonate 125ml to 250ml / 30min up to 1000ml/24h to maintain plasma pH equal or greater than 7.30</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Bicarbonate</intervention_name>
    <description>Intravenous 4.2% Sodium Bicarbonate 125ml to 250ml / 30min up to 1000ml/24h to maintain plasma pH equal or greater than 7.30</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age of 18 yo or above,

          -  Critically ill patient with a SOFA score of 4 or above,

          -  Lactatemia of 2mmol/l or above, with pH of 7.20 or below and PaCO2 of 45mmHg or below
             and bicarbonatemia of 20mmol/l or below

        Exclusion Criteria:

          -  Administration of Sodium Bicarbonate 24 hours before inclusion

          -  Single respiratory disorder (PaCO2 &gt; 50 mmHg, Bicarbonatemia equal or higher than
             (PaCO2-40)/10 + 24

          -  Acute diarrhea, ileostomy or biliary drainage

          -  Stage IV kidney failure or chronic dialysis

          -  Tubular acidosis, ketoacidosis, high anion gap acids poisoning (PEG, aspirin,
             methanol)

          -  PaCO2 equal to 45mmHg or above and spontaneous breathing, pregnancy, protected
             patients, moribund patient (life expectancy of 48h or below)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boris JUNG, MD</last_name>
    <phone>0467337271</phone>
    <email>b-jung@chu-montpellier.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Samir Jaber, MD</last_name>
    <phone>0467337271</phone>
    <email>s-jaber@chu-montpellier.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>DAR St Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samir Jaber, MD, PhD</last_name>
      <phone>33467337271</phone>
      <email>s-jaber@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Boris Jung, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Kellum JA, Levin N, Bouman C, Lameire N. Developing a consensus classification system for acute renal failure. Curr Opin Crit Care. 2002 Dec;8(6):509-14. Review.</citation>
    <PMID>12454534</PMID>
  </reference>
  <reference>
    <citation>Dubin A, Menises MM, Masevicius FD, Moseinco MC, Kutscherauer DO, Ventrice E, Laffaire E, Estenssoro E. Comparison of three different methods of evaluation of metabolic acid-base disorders. Crit Care Med. 2007 May;35(5):1264-70.</citation>
    <PMID>17334252</PMID>
  </reference>
  <reference>
    <citation>Smith I, Kumar P, Molloy S, Rhodes A, Newman PJ, Grounds RM, Bennett ED. Base excess and lactate as prognostic indicators for patients admitted to intensive care. Intensive Care Med. 2001 Jan;27(1):74-83.</citation>
    <PMID>11280677</PMID>
  </reference>
  <reference>
    <citation>Gunnerson KJ, Saul M, He S, Kellum JA. Lactate versus non-lactate metabolic acidosis: a retrospective outcome evaluation of critically ill patients. Crit Care. 2006 Feb;10(1):R22.</citation>
    <PMID>16507145</PMID>
  </reference>
  <reference>
    <citation>Jung B, Rimmele T, Le Goff C, Chanques G, Corne P, Jonquet O, Muller L, Lefrant JY, Guervilly C, Papazian L, Allaouchiche B, Jaber S; AzuRea Group. Severe metabolic or mixed acidemia on intensive care unit admission: incidence, prognosis and administration of buffer therapy. A prospective, multiple-center study. Crit Care. 2011;15(5):R238. doi: 10.1186/cc10487. Epub 2011 Oct 13.</citation>
    <PMID>21995879</PMID>
  </reference>
  <reference>
    <citation>Husain FA, Martin MJ, Mullenix PS, Steele SR, Elliott DC. Serum lactate and base deficit as predictors of mortality and morbidity. Am J Surg. 2003 May;185(5):485-91.</citation>
    <PMID>12727572</PMID>
  </reference>
  <reference>
    <citation>Kellum JA. Clinical review: reunification of acid-base physiology. Crit Care. 2005 Oct 5;9(5):500-7. Epub 2005 Aug 5. Review.</citation>
    <PMID>16277739</PMID>
  </reference>
  <reference>
    <citation>Forsythe SM, Schmidt GA. Sodium bicarbonate for the treatment of lactic acidosis. Chest. 2000 Jan;117(1):260-7. Review.</citation>
    <PMID>10631227</PMID>
  </reference>
  <reference>
    <citation>Fencl V, Jabor A, Kazda A, Figge J. Diagnosis of metabolic acid-base disturbances in critically ill patients. Am J Respir Crit Care Med. 2000 Dec;162(6):2246-51.</citation>
    <PMID>11112147</PMID>
  </reference>
  <reference>
    <citation>Kellum JA, Song M, Almasri E. Hyperchloremic acidosis increases circulating inflammatory molecules in experimental sepsis. Chest. 2006 Oct;130(4):962-7.</citation>
    <PMID>17035425</PMID>
  </reference>
  <reference>
    <citation>Kellum JA, Song M, Venkataraman R. Effects of hyperchloremic acidosis on arterial pressure and circulating inflammatory molecules in experimental sepsis. Chest. 2004 Jan;125(1):243-8.</citation>
    <PMID>14718447</PMID>
  </reference>
  <reference>
    <citation>Morimoto Y, Morimoto Y, Kemmotsu O, Alojado ES. Extracellular acidosis delays cell death against glucose-oxygen deprivation in neuroblastoma x glioma hybrid cells. Crit Care Med. 1997 May;25(5):841-7.</citation>
    <PMID>9187605</PMID>
  </reference>
  <reference>
    <citation>Laffey JG, O'Croinin D, McLoughlin P, Kavanagh BP. Permissive hypercapnia--role in protective lung ventilatory strategies. Intensive Care Med. 2004 Mar;30(3):347-56. Epub 2004 Jan 14. Review.</citation>
    <PMID>14722644</PMID>
  </reference>
  <reference>
    <citation>Kraut JA, Madias NE. Metabolic acidosis: pathophysiology, diagnosis and management. Nat Rev Nephrol. 2010 May;6(5):274-85. doi: 10.1038/nrneph.2010.33. Epub 2010 Mar 23. Review.</citation>
    <PMID>20308999</PMID>
  </reference>
  <reference>
    <citation>Cohen MV, Yang XM, Downey JM. The pH hypothesis of postconditioning: staccato reperfusion reintroduces oxygen and perpetuates myocardial acidosis. Circulation. 2007 Apr 10;115(14):1895-903. Epub 2007 Mar 26.</citation>
    <PMID>17389262</PMID>
  </reference>
  <reference>
    <citation>Bersin RM, Chatterjee K, Arieff AI. Metabolic and hemodynamic consequences of sodium bicarbonate administration in patients with heart disease. Am J Med. 1989 Jul;87(1):7-14.</citation>
    <PMID>2741982</PMID>
  </reference>
  <reference>
    <citation>Cooper DJ, Walley KR, Wiggs BR, Russell JA. Bicarbonate does not improve hemodynamics in critically ill patients who have lactic acidosis. A prospective, controlled clinical study. Ann Intern Med. 1990 Apr 1;112(7):492-8.</citation>
    <PMID>2156475</PMID>
  </reference>
  <reference>
    <citation>Mathieu D, Neviere R, Billard V, Fleyfel M, Wattel F. Effects of bicarbonate therapy on hemodynamics and tissue oxygenation in patients with lactic acidosis: a prospective, controlled clinical study. Crit Care Med. 1991 Nov;19(11):1352-6.</citation>
    <PMID>1935152</PMID>
  </reference>
  <reference>
    <citation>El-Solh AA, Abou Jaoude P, Porhomayon J. Bicarbonate therapy in the treatment of septic shock: a second look. Intern Emerg Med. 2010 Aug;5(4):341-7. doi: 10.1007/s11739-010-0351-3. Epub 2010 Feb 19. Erratum in: Intern Emerg Med. 2010 Aug;5(4):367.</citation>
    <PMID>20169423</PMID>
  </reference>
  <reference>
    <citation>Fang ZX, Li YF, Zhou XQ, Zhang Z, Zhang JS, Xia HM, Xing GP, Shu WP, Shen L, Yin GQ. Effects of resuscitation with crystalloid fluids on cardiac function in patients with severe sepsis. BMC Infect Dis. 2008 Apr 17;8:50. doi: 10.1186/1471-2334-8-50.</citation>
    <PMID>18419825</PMID>
  </reference>
  <reference>
    <citation>Kraut JA, Kurtz I. Use of base in the treatment of acute severe organic acidosis by nephrologists and critical care physicians: results of an online survey. Clin Exp Nephrol. 2006 Jun;10(2):111-7.</citation>
    <PMID>16791396</PMID>
  </reference>
  <reference>
    <citation>Kellum JA. Disorders of acid-base balance. Crit Care Med. 2007 Nov;35(11):2630-6. Review.</citation>
    <PMID>17893626</PMID>
  </reference>
  <reference>
    <citation>Kraut JA, Kurtz I. Metabolic acidosis of CKD: diagnosis, clinical characteristics, and treatment. Am J Kidney Dis. 2005 Jun;45(6):978-93. Review.</citation>
    <PMID>15957126</PMID>
  </reference>
  <reference>
    <citation>Shah SN, Abramowitz M, Hostetter TH, Melamed ML. Serum bicarbonate levels and the progression of kidney disease: a cohort study. Am J Kidney Dis. 2009 Aug;54(2):270-7. doi: 10.1053/j.ajkd.2009.02.014. Epub 2009 Apr 25.</citation>
    <PMID>19394734</PMID>
  </reference>
  <reference>
    <citation>Brar SS, Shen AY, Jorgensen MB, Kotlewski A, Aharonian VJ, Desai N, Ree M, Shah AI, Burchette RJ. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA. 2008 Sep 3;300(9):1038-46. doi: 10.1001/jama.300.9.1038.</citation>
    <PMID>18768415</PMID>
  </reference>
  <reference>
    <citation>Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC. Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med. 2008 Feb 19;148(4):284-94. Erratum in: Ann Intern Med. 2008 Aug 5;149(3):219.</citation>
    <PMID>18283206</PMID>
  </reference>
  <reference>
    <citation>From AM, Bartholmai BJ, Williams AW, Cha SS, Pflueger A, McDonald FS. Sodium bicarbonate is associated with an increased incidence of contrast nephropathy: a retrospective cohort study of 7977 patients at mayo clinic. Clin J Am Soc Nephrol. 2008 Jan;3(1):10-8. Epub 2007 Dec 5.</citation>
    <PMID>18057306</PMID>
  </reference>
  <reference>
    <citation>Vincent JL, de Mendonça A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on &quot;sepsis-related problems&quot; of the European Society of Intensive Care Medicine. Crit Care Med. 1998 Nov;26(11):1793-800.</citation>
    <PMID>9824069</PMID>
  </reference>
  <reference>
    <citation>Brochard L, Abroug F, Brenner M, Broccard AF, Danner RL, Ferrer M, Laghi F, Magder S, Papazian L, Pelosi P, Polderman KH; ATS/ERS/ESICM/SCCM/SRLF Ad Hoc Committee on Acute Renal Failure. An Official ATS/ERS/ESICM/SCCM/SRLF Statement: Prevention and Management of Acute Renal Failure in the ICU Patient: an international consensus conference in intensive care medicine. Am J Respir Crit Care Med. 2010 May 15;181(10):1128-55. doi: 10.1164/rccm.200711-1664ST.</citation>
    <PMID>20460549</PMID>
  </reference>
  <reference>
    <citation>Ferrer M, Sellarés J, Valencia M, Carrillo A, Gonzalez G, Badia JR, Nicolas JM, Torres A. Non-invasive ventilation after extubation in hypercapnic patients with chronic respiratory disorders: randomised controlled trial. Lancet. 2009 Sep 26;374(9695):1082-8. doi: 10.1016/S0140-6736(09)61038-2. Epub 2009 Aug 12.</citation>
    <PMID>19682735</PMID>
  </reference>
  <reference>
    <citation>RENAL Replacement Therapy Study Investigators, Bellomo R, Cass A, Cole L, Finfer S, Gallagher M, Lo S, McArthur C, McGuinness S, Myburgh J, Norton R, Scheinkestel C, Su S. Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med. 2009 Oct 22;361(17):1627-38. doi: 10.1056/NEJMoa0902413.</citation>
    <PMID>19846848</PMID>
  </reference>
  <reference>
    <citation>American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005 Feb 15;171(4):388-416.</citation>
    <PMID>15699079</PMID>
  </reference>
  <reference>
    <citation>Hooton TM, Bradley SF, Cardenas DD, Colgan R, Geerlings SE, Rice JC, Saint S, Schaeffer AJ, Tambayh PA, Tenke P, Nicolle LE; Infectious Diseases Society of America. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis. 2010 Mar 1;50(5):625-63.</citation>
    <PMID>20175247</PMID>
  </reference>
  <reference>
    <citation>Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, Raad II, Rijnders BJ, Sherertz RJ, Warren DK. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2009 Jul 1;49(1):1-45. doi: 10.1086/599376. Erratum in: Clin Infect Dis. 2010 Apr 1;50(7):1079. Dosage error in article text. Clin Infect Dis. 2010 Feb 1;50(3):457.</citation>
    <PMID>19489710</PMID>
  </reference>
  <reference>
    <citation>Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA. 1993 Dec 22-29;270(24):2957-63. Erratum in: JAMA 1994 May 4;271(17):1321.</citation>
    <PMID>8254858</PMID>
  </reference>
  <reference>
    <citation>Jaber S, Jung B, Sebbane M, Ramonatxo M, Capdevila X, Mercier J, Eledjam JJ, Matecki S. Alteration of the piglet diaphragm contractility in vivo and its recovery after acute hypercapnia. Anesthesiology. 2008 Apr;108(4):651-8. doi: 10.1097/ALN.0b013e31816725a6.</citation>
    <PMID>18362597</PMID>
  </reference>
  <reference>
    <citation>Ichai C, Massa H, Hubert S. c. In: SAS EM, editor. EMC Anesthésie-Réanimation. Paris; 2006.</citation>
  </reference>
  <reference>
    <citation>Correction de l'acidose métabolique en réanimation. 1999 [cited; Available from: http://www.urgences-serveur.fr/IMG/pdf/correction_acidose.pdf</citation>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2015</study_first_submitted>
  <study_first_submitted_qc>June 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2015</study_first_posted>
  <last_update_submitted>April 20, 2017</last_update_submitted>
  <last_update_submitted_qc>April 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acidosis</keyword>
  <keyword>shock</keyword>
  <keyword>sodium bicarbonate</keyword>
  <keyword>renal replacement therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Acidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

